Recommend Email

Find another Doctor or Researcher

A photo of Bruce Trapnell.
High Res

Bruce C. Trapnell, MS, MD

Director, Transitional Pulmonary Science Center

Attending Physician, Pulmonologist - Research, Adult Clinical, Division of Pulmonary Medicine

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6361

Fax 513-636-3723

Email bruce.trapnell@cchmc.org

Clinical

Research on rare lung diseases including pulmonary alveolar proteinosis; cystic fibrosis; alpha-1 antitrypsin deficiency; lymphangioleiomyomatosis

Research

Alveolar macrophage function; molecular techniques using gene knockout, transgenic and conditional gene expression mouse models and non-human primates, in vitro and in vivo viral gene transfer, and bone marrow transplantation

Dr. Trapnell received his medical degree from the University of Maryland in 1985 and medical residency training at The Ohio State University Hospitals. He completed a fellowship in pulmonary medicine and then served as attending physician and senior attending physician at the Clinical Center of the National Institutes of Health. Subsequently, he served as vice president and director of the Division of Pulmonary and Virology Studies at Genetic Therapy, Incorporated, a subsidiary of Novartis.

In 1997, Dr. Trapnell joined Cincinnati Children’s Hospital Medical Center and is now a professor of Medicine and Pediatrics at the UC College of Medicine. At Cincinnati Children's, he directed Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center for more than a decade and participated in numerous clinical trials as principal investigator including studies leading to FDA-approval of Creon® and Pancreaze®. He established and directs the Rare Lung Diseases Clinical Research Consortium (RLDC) in which a study led by Frank McCormack resulted in FDA approval of Sirolimus® as therapy of Lymphangioleiomyomatosis.

Dr. Trapnell’s research group established that GM-CSF autoantibodies caused the rare lung disease autoimmune pulmonary alveolar proteinosis and established clinical laboratory tests for its diagnosis and identified hereditary pulmonary alveolar proteinosis as a new genetic disease caused by mutations in CSF2RA and CSF2RB. His research group developed a novel type of cell transplantation, pulmonary macrophage transplantation, and is currently translating it for testing as therapy in patients with the disease. The group also contributed to the identification, characterization, and methods for diagnosis of indium-related lung disease.

An ardent patient advocate, Dr. Trapnell has worked with patient foundations for cystic fibrosis (CF), alpha-1-antitrypsin deficiency, pulmonary alveolar proteinosis, lymphangioleiomyomatosis, and childhood interstitial lung diseases. He has served as past scientific director for the Alpha-1 Foundation and as co-founder and current scientific director of the Pulmonary Alveolar Proteinosis Foundation. Since coming to Cincinnati, he has provided training in basic, clinical, and translational research at pre- and post-doctoral levels.

BS: Biochemistry, University of Maryland, College Park, MD, 1978.

MS: Genetics, The George Washington University, Washington, DC, 1981.

MD: University of Maryland School of Medicine, Baltimore, MD, 1984.

Residency: Internal Medicine, The Ohio State University Hospitals, Columbus, OH, 1987.

Fellowship: Pulmonary Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1989.

Certification: Diplomat in Internal Medicine, American Board of Internal Medicine, 1987; Diplomat, National Board of Medical Examiners, 1987; Diplomat in Pulmonary Medicine, American Board of Internal Medicine, 2000.

View PubMed Publications

Suzuki T, Arumugam P, Sakagami T, Lachmann N, Chalk C, Sallese A, Abe S, Trapnell C, Carey B, Moritz T, Malik P, Lutzko C, Wood RD, and Trapnell BC. Pulmonary macrophage transplantation therapy. Nature. 2014;514:450-54.

Suzuki T, Mayhew C, Sallese A, Chalk C, Carey BC, Malik P, Wood RE, Trapnell BC. Use of Induced Pluripotent Stem Cells to Recapitulate PAP Pathogenesis. Am J Resp Crit Care Med. 2014;189:183-93.

Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Yachnis A, Knop DR, YE G-J, Brantly ML, Calcedo R, Somanathan S, Richman LR, Vonderheide RH, Wilson JM, Flotte TR. Persistence of Transgene Expression Associated with In Situ Regulatory T Cell Responses in Humans 12 Months After Administration of a Recombinant AAV Vector. J Clin Inv. 2013;123(12):5310-5318.

Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE. Phase-2 Placebo-controlled Trial of Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis patients. Am J Resp Crit Care Med. 2012;185:171-8.

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldgerg HG, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveria-Dasilva AM, Lee H-S, Krischer JP, Trapnell BC. Multicenter international lymphangioleiomyomatosis efficacy and safety of sirolimus (MILES) trial. N Engl J Med. 2011;364:1505-1606.

Trapnell BC, Strausbaugh S, Woo MS, Tong S-Y, Silber SA, Mulberg AE, Leitz G. Efficacy and safety of PANCREAZETM for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cystic Fibrosis. 2011;10:350-5.

Suzuki T, Maranda B, Sakagami T, Carey BC, Chalk C, and Trapnell BC. Hereditary PAP Caused by Recessive CSF2RB mutations that Impair GM-CSF Receptor Signaling. Eur Resp J. 2011;37:201-4.

Suzuki T, Sakagami T, Young L, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC. Hereditary PAP: Pathogenesis, Presentation, Diagnosis, and Therapy. Am J Resp Crit Care Med. 2010;182:1292-304.

Sakagami T, Uchida K, Suzuki T, Carey B, Wood R, Wert S, Whitsett J, Trapnell B. Human GM-CSF Autoantibodies and Reproduction of PAP. New Engl J Med. 2009;361:2679-81.

Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Creon for Treatment of Exocrine Pancreatic Insufficiency. J Cystic Fibrosis. 2009;8:370-377.

Pathogenesis-Based Diagnostics and Pharmacotherapeutics for PAP. Principal Investigator. National Institutes of Health/National Heart, Lung, and Blood Institute. Apr 2016-Mar 2020. R01 HL085453.

Macrophage-Based Gene Therapy for Hereditary Pulmonary Alveolar Proteinosis. Principal Investigator. National Institutes of Health/National Heart, Lung, and Blood Institute. May 2014-Apr 2018. R01 HL118342.

RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung Diseases. Principal Investigator. National Center for Advancing Translational Sciences & National Institutes of Health/National Heart, Lung, and Blood Institute. Sep 2014-Aug 2019. U54 HL127672.

Aerosol Therapy of autoimmune pulmonary alveolar proteinosis. Principal Investigator. National Institutes of Health/National Center for Advancing Translational Sciences. 2012-Present. Therapeutics for Rare and Neglected Diseases Project.

Lung and Cardiovascular Development and Disease Pathogenesis Training Program. Co-Principal Investigator (Whitsett, Trapnell, McCormack). National Institutes of Health/National Heart, Lung, and Blood Institute. Jul 1994-Jun 2019. T32 HL007752.

Causes and Consequences of Neutrophil Dysfunction in Pediatric Crohn’s Disease. Co-Investigator. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. Sep 2013-Jul 2018. R01 DK098231.

Related Professionals

Donate to Cincinnati Children's.

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462

© 1999-2019 Cincinnati Children's Hospital Medical Center. All rights reserved.

Visit the U.S. News website. Best Places to Work Logo